EGFR Targeting of Solid Tumors-Reference-Cited by-同舟云学术

EGFR Targeting of Solid Tumors

Published:2007-07 Issue:3 Volume:14 Page:295-304
ISSN:1073-2748
Container-title:Cancer Control
language:en
Short-container-title:Cancer Control

Author:

Rocha-Lima Caio M.¹,Soares Heloisa P.¹²,Raez Luis E.¹,Singal Rakesh¹³

Affiliation:

1. Department of Hematology/Oncology at the Sylvester Comprehensive Cancer Center, Miami, Florida at the University of Miami School of Medicine, Miami, Florida.

2. H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida

3. Miami Veterans Administration Medical Center at the University of Miami School of Medicine, Miami, Florida.

Publisher

SAGE Publications

Subject

Oncology,Hematology,General Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/107327480701400313

Reference69 articles.

1. Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1

2. Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2

3. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

4. EGFR and cancer prognosis

5. Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

Cited by 192 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research on enzymatic co-assembly nanomedicine in oral squamous cell carcinoma;Precision Medicine and Engineering;2024-09

2. Gefitinib-Induced Severe Dermatological Adverse Reactions: A Case Report and Pharmacogenetic Profile;Pharmaceuticals;2024-08-07

3. Adverse effects of anti-cancer biologics on the ocular surface;Current Opinion in Allergy & Clinical Immunology;2024-07-04

4. Computational insights into the stereo-selectivity of catechins for the inhibition of the cancer therapeutic target EGFR kinase;Frontiers in Pharmacology;2024-01-11

5. Exploring KRAS-mutant pancreatic ductal adenocarcinoma: a model validation study;Frontiers in Immunology;2024-01-10